The FDA has expressed concerns about compounded peptides, particularly those that have not been approved for any medical use
AmB is highly efficacious but also has associated toxicity such as includes fever, nausea, vomiting, rigors, hypertension or hypotension, and hypoxia when administered in its free deoxycholate form which has been overcome in its liposomal formulation (Laniado-Laborn and Cabrales-Vargas, 2009
Reactive astrocytes and therapeutic potential in focal ischemic stroke
[2] [3] [4] [5] A separate product, semaglutide subcutaneous injection, is indicated as an adjunct to lifestyle modifications for weight loss and chronic weight management in obese (BMI 30 kg/m2 or greater) or overweight adults (BMI 27 kg/m2 or greater) with at least 1 weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)